Affinity Asset Advisors LLC Buys Shares of 10,000 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Affinity Asset Advisors LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 10,000 shares of the company’s stock, valued at approximately $1,318,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Lindbrook Capital LLC increased its holdings in Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after acquiring an additional 96 shares in the last quarter. EdgeRock Capital LLC purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter worth about $31,000. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter worth about $33,000. Headinvest LLC purchased a new stake in shares of Neurocrine Biosciences during the third quarter worth about $28,000. Finally, Sunbelt Securities Inc. grew its holdings in shares of Neurocrine Biosciences by 34.3% during the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock worth $37,000 after buying an additional 83 shares in the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock traded up $0.65 during midday trading on Wednesday, hitting $134.13. The company had a trading volume of 49,297 shares, compared to its average volume of 828,816. The business’s 50 day simple moving average is $138.11 and its two-hundred day simple moving average is $133.44. The stock has a market cap of $13.50 billion, a PE ratio of 36.77 and a beta of 0.36. Neurocrine Biosciences, Inc. has a 1-year low of $92.61 and a 1-year high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The company had revenue of $515.30 million during the quarter, compared to analyst estimates of $512.21 million. On average, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current fiscal year.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Stephen A. Sherwin sold 40,000 shares of Neurocrine Biosciences stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the sale, the director now owns 26,504 shares in the company, valued at $3,537,223.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Ingrid Delaet sold 1,800 shares of Neurocrine Biosciences stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $140.03, for a total value of $252,054.00. Following the completion of the transaction, the insider now directly owns 7,507 shares of the company’s stock, valued at $1,051,205.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Stephen A. Sherwin sold 40,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total value of $5,338,400.00. Following the completion of the transaction, the director now directly owns 26,504 shares of the company’s stock, valued at $3,537,223.84. The disclosure for this sale can be found here. Insiders have sold 212,497 shares of company stock worth $29,263,354 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Mizuho increased their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research report on Thursday, February 8th. HC Wainwright increased their target price on shares of Neurocrine Biosciences from $150.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Oppenheimer increased their target price on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Finally, Barclays raised their price objective on shares of Neurocrine Biosciences from $150.00 to $169.00 and gave the company an “overweight” rating in a research report on Thursday, May 2nd. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $150.85.

View Our Latest Research Report on NBIX

Neurocrine Biosciences Company Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Featured Articles

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.